nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—PTGS2—muscle cancer	0.501	1	CbGaD
Celecoxib—ABCC4—Methotrexate—muscle cancer	0.0516	0.34	CbGbCtD
Celecoxib—PTGS2—Etoposide—muscle cancer	0.0459	0.303	CbGbCtD
Celecoxib—ALB—Methotrexate—muscle cancer	0.0191	0.126	CbGbCtD
Celecoxib—CYP3A4—Vincristine—muscle cancer	0.0099	0.0653	CbGbCtD
Celecoxib—CYP2D6—Doxorubicin—muscle cancer	0.00973	0.0642	CbGbCtD
Celecoxib—CYP3A4—Etoposide—muscle cancer	0.00907	0.0599	CbGbCtD
Celecoxib—CYP3A4—Doxorubicin—muscle cancer	0.00618	0.0408	CbGbCtD
Celecoxib—PDPK1—embryo—muscle cancer	0.00468	0.0688	CbGeAlD
Celecoxib—PDPK1—renal system—muscle cancer	0.00354	0.0521	CbGeAlD
Celecoxib—PDPK1—vagina—muscle cancer	0.00257	0.0377	CbGeAlD
Celecoxib—PTGS2—hindlimb—muscle cancer	0.00253	0.0372	CbGeAlD
Celecoxib—MAPK14—embryo—muscle cancer	0.0025	0.0368	CbGeAlD
Celecoxib—Etoricoxib—PTGS2—muscle cancer	0.00242	1	CrCbGaD
Celecoxib—PDPK1—head—muscle cancer	0.00237	0.0349	CbGeAlD
Celecoxib—PDPK1—testis—muscle cancer	0.00229	0.0337	CbGeAlD
Celecoxib—PTGS2—appendage—muscle cancer	0.00217	0.0319	CbGeAlD
Celecoxib—MAPK14—smooth muscle tissue—muscle cancer	0.00197	0.0289	CbGeAlD
Celecoxib—MAPK14—renal system—muscle cancer	0.0019	0.0279	CbGeAlD
Celecoxib—CA14—cardiac atrium—muscle cancer	0.00165	0.0243	CbGeAlD
Celecoxib—CA9—tendon—muscle cancer	0.00152	0.0223	CbGeAlD
Celecoxib—MAPK14—tendon—muscle cancer	0.00148	0.0217	CbGeAlD
Celecoxib—CA14—tendon—muscle cancer	0.00144	0.0212	CbGeAlD
Celecoxib—CA12—renal system—muscle cancer	0.00144	0.0211	CbGeAlD
Celecoxib—CA6—head—muscle cancer	0.00143	0.0211	CbGeAlD
Celecoxib—MAPK14—bone marrow—muscle cancer	0.00143	0.0211	CbGeAlD
Celecoxib—MAPK14—vagina—muscle cancer	0.00137	0.0202	CbGeAlD
Celecoxib—MAPK14—head—muscle cancer	0.00127	0.0186	CbGeAlD
Celecoxib—CA9—testis—muscle cancer	0.00126	0.0185	CbGeAlD
Celecoxib—MAPK14—testis—muscle cancer	0.00123	0.018	CbGeAlD
Celecoxib—CA5B—cardiac atrium—muscle cancer	0.00116	0.017	CbGeAlD
Celecoxib—CA5B—tendon—muscle cancer	0.00101	0.0148	CbGeAlD
Celecoxib—CA2—embryo—muscle cancer	0.000976	0.0143	CbGeAlD
Celecoxib—ABCC4—renal system—muscle cancer	0.000969	0.0142	CbGeAlD
Celecoxib—CA12—head—muscle cancer	0.000962	0.0141	CbGeAlD
Celecoxib—CA5B—vagina—muscle cancer	0.000935	0.0137	CbGeAlD
Celecoxib—CA4—renal system—muscle cancer	0.000891	0.0131	CbGeAlD
Celecoxib—CA5B—head—muscle cancer	0.000863	0.0127	CbGeAlD
Celecoxib—ORM1—bone marrow—muscle cancer	0.000863	0.0127	CbGeAlD
Celecoxib—CA5B—testis—muscle cancer	0.000834	0.0123	CbGeAlD
Celecoxib—CA4—cardiac atrium—muscle cancer	0.000798	0.0117	CbGeAlD
Celecoxib—CA2—smooth muscle tissue—muscle cancer	0.000767	0.0113	CbGeAlD
Celecoxib—ABCC4—tendon—muscle cancer	0.000756	0.0111	CbGeAlD
Celecoxib—CA2—renal system—muscle cancer	0.000738	0.0109	CbGeAlD
Celecoxib—ABCC4—bone marrow—muscle cancer	0.000732	0.0108	CbGeAlD
Celecoxib—PTGS2—embryo—muscle cancer	0.00072	0.0106	CbGeAlD
Celecoxib—CA4—tendon—muscle cancer	0.000695	0.0102	CbGeAlD
Celecoxib—CA4—bone marrow—muscle cancer	0.000673	0.0099	CbGeAlD
Celecoxib—CA2—cardiac atrium—muscle cancer	0.000661	0.00972	CbGeAlD
Celecoxib—ABCC4—head—muscle cancer	0.000648	0.00953	CbGeAlD
Celecoxib—ALB—testis—muscle cancer	0.000647	0.00951	CbGeAlD
Celecoxib—ABCC4—testis—muscle cancer	0.000626	0.0092	CbGeAlD
Celecoxib—CA4—head—muscle cancer	0.000596	0.00876	CbGeAlD
Celecoxib—CA2—tendon—muscle cancer	0.000576	0.00847	CbGeAlD
Celecoxib—CA4—testis—muscle cancer	0.000576	0.00846	CbGeAlD
Celecoxib—PTGS2—smooth muscle tissue—muscle cancer	0.000566	0.00832	CbGeAlD
Celecoxib—CA2—bone marrow—muscle cancer	0.000558	0.00821	CbGeAlD
Celecoxib—PTGS2—renal system—muscle cancer	0.000545	0.00801	CbGeAlD
Celecoxib—CA2—vagina—muscle cancer	0.000535	0.00786	CbGeAlD
Celecoxib—CA2—head—muscle cancer	0.000494	0.00726	CbGeAlD
Celecoxib—CA2—testis—muscle cancer	0.000477	0.00701	CbGeAlD
Celecoxib—CYP3A4—renal system—muscle cancer	0.000476	0.007	CbGeAlD
Celecoxib—CYP2D6—renal system—muscle cancer	0.000469	0.00689	CbGeAlD
Celecoxib—PTGS2—tendon—muscle cancer	0.000426	0.00625	CbGeAlD
Celecoxib—PTGS2—bone marrow—muscle cancer	0.000412	0.00606	CbGeAlD
Celecoxib—PTGS2—vagina—muscle cancer	0.000395	0.0058	CbGeAlD
Celecoxib—PTGS2—head—muscle cancer	0.000365	0.00536	CbGeAlD
Celecoxib—CYP2D6—head—muscle cancer	0.000314	0.00461	CbGeAlD
Celecoxib—CYP2D6—testis—muscle cancer	0.000303	0.00445	CbGeAlD
Celecoxib—PDPK1—DAP12 signaling—KIT—muscle cancer	0.000283	0.0025	CbGpPWpGaD
Celecoxib—PDPK1—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	0.000279	0.00246	CbGpPWpGaD
Celecoxib—ABCC4—Fluoropyrimidine Activity—TP53—muscle cancer	0.000274	0.00241	CbGpPWpGaD
Celecoxib—MAPK14—p53 pathway—CDKN2A—muscle cancer	0.000271	0.00239	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 interactions—KIT—muscle cancer	0.000266	0.00235	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by FGFR in disease—KIT—muscle cancer	0.000266	0.00235	CbGpPWpGaD
Celecoxib—PDPK1—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.000266	0.00235	CbGpPWpGaD
Celecoxib—MAPK14—EGF/EGFR Signaling Pathway—FOXO4—muscle cancer	0.000264	0.00233	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR—KIT—muscle cancer	0.000264	0.00233	CbGpPWpGaD
Celecoxib—CA12—Metabolism—FH—muscle cancer	0.000264	0.00232	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—HMGA1—muscle cancer	0.000264	0.00232	CbGpPWpGaD
Celecoxib—MAPK14—p53 pathway—MDM2—muscle cancer	0.000263	0.00231	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR in Cancer—KIT—muscle cancer	0.000262	0.00231	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by PDGF—KIT—muscle cancer	0.00026	0.0023	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—CD34—muscle cancer	0.00026	0.00229	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—MYOG—muscle cancer	0.000258	0.00227	CbGpPWpGaD
Celecoxib—PDPK1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.000253	0.00223	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by SCF-KIT—MDM2—muscle cancer	0.000252	0.00222	CbGpPWpGaD
Celecoxib—MAPK14—Regulation of retinoblastoma protein—CDKN2A—muscle cancer	0.000247	0.00218	CbGpPWpGaD
Celecoxib—PDPK1—B Cell Activation—KIT—muscle cancer	0.000247	0.00217	CbGpPWpGaD
Celecoxib—Cough—Etoposide—muscle cancer	0.000242	0.00148	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Vincristine—muscle cancer	0.000241	0.00147	CcSEcCtD
Celecoxib—PDPK1—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000241	0.00212	CbGpPWpGaD
Celecoxib—Fatigue—Vincristine—muscle cancer	0.00024	0.00147	CcSEcCtD
Celecoxib—MAPK14—Regulation of retinoblastoma protein—MDM2—muscle cancer	0.00024	0.00212	CbGpPWpGaD
Celecoxib—Hyponatraemia—Doxorubicin—muscle cancer	0.000239	0.00147	CcSEcCtD
Celecoxib—Hypertension—Etoposide—muscle cancer	0.000239	0.00146	CcSEcCtD
Celecoxib—Constipation—Vincristine—muscle cancer	0.000239	0.00146	CcSEcCtD
Celecoxib—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.000238	0.00146	CcSEcCtD
Celecoxib—Osteoarthritis—Doxorubicin—muscle cancer	0.000238	0.00146	CcSEcCtD
Celecoxib—PDPK1—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	0.000238	0.0021	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by NGF—FOXO1—muscle cancer	0.000238	0.0021	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by ERBB4—MDM2—muscle cancer	0.000237	0.00209	CbGpPWpGaD
Celecoxib—PDPK1—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000236	0.00208	CbGpPWpGaD
Celecoxib—Chest pain—Etoposide—muscle cancer	0.000236	0.00144	CcSEcCtD
Celecoxib—Eosinophilia—Methotrexate—muscle cancer	0.000236	0.00144	CcSEcCtD
Celecoxib—Migraine—Doxorubicin—muscle cancer	0.000235	0.00144	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000234	0.00143	CcSEcCtD
Celecoxib—Pancreatitis—Methotrexate—muscle cancer	0.000233	0.00143	CcSEcCtD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000231	0.00204	CbGpPWpGaD
Celecoxib—Face oedema—Doxorubicin—muscle cancer	0.00023	0.00141	CcSEcCtD
Celecoxib—Hypersensitivity—Dactinomycin—muscle cancer	0.00023	0.00141	CcSEcCtD
Celecoxib—MAPK14—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	0.000229	0.00202	CbGpPWpGaD
Celecoxib—Gastrointestinal pain—Vincristine—muscle cancer	0.000228	0.0014	CcSEcCtD
Celecoxib—Confusional state—Etoposide—muscle cancer	0.000228	0.00139	CcSEcCtD
Celecoxib—PDPK1—Downstream signal transduction—MDM2—muscle cancer	0.000226	0.002	CbGpPWpGaD
Celecoxib—Pancytopenia—Methotrexate—muscle cancer	0.000226	0.00138	CcSEcCtD
Celecoxib—Anaphylactic shock—Etoposide—muscle cancer	0.000226	0.00138	CcSEcCtD
Celecoxib—PDPK1—Signaling by FGFR—MDM2—muscle cancer	0.000225	0.00199	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by VEGF—VEGFA—muscle cancer	0.000225	0.00198	CbGpPWpGaD
Celecoxib—Infection—Etoposide—muscle cancer	0.000224	0.00137	CcSEcCtD
Celecoxib—Ataxia—Doxorubicin—muscle cancer	0.000224	0.00137	CcSEcCtD
Celecoxib—PDPK1—Signaling by ERBB2—MDM2—muscle cancer	0.000224	0.00198	CbGpPWpGaD
Celecoxib—Asthenia—Dactinomycin—muscle cancer	0.000224	0.00137	CcSEcCtD
Celecoxib—Blood creatinine increased—Doxorubicin—muscle cancer	0.000223	0.00137	CcSEcCtD
Celecoxib—PDPK1—DAP12 signaling—MDM2—muscle cancer	0.000223	0.00197	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways in Glioblastoma—TP53—muscle cancer	0.000223	0.00196	CbGpPWpGaD
Celecoxib—Dysuria—Methotrexate—muscle cancer	0.000223	0.00136	CcSEcCtD
Celecoxib—Thrombocytopenia—Etoposide—muscle cancer	0.000221	0.00135	CcSEcCtD
Celecoxib—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000221	0.00135	CcSEcCtD
Celecoxib—Tachycardia—Etoposide—muscle cancer	0.000221	0.00135	CcSEcCtD
Celecoxib—Body temperature increased—Vincristine—muscle cancer	0.00022	0.00135	CcSEcCtD
Celecoxib—Abdominal pain—Vincristine—muscle cancer	0.00022	0.00135	CcSEcCtD
Celecoxib—Liver function test abnormal—Doxorubicin—muscle cancer	0.00022	0.00135	CcSEcCtD
Celecoxib—PDPK1—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.00022	0.00194	CbGpPWpGaD
Celecoxib—Skin disorder—Etoposide—muscle cancer	0.000219	0.00134	CcSEcCtD
Celecoxib—Dry skin—Doxorubicin—muscle cancer	0.000219	0.00134	CcSEcCtD
Celecoxib—Hyperhidrosis—Etoposide—muscle cancer	0.000218	0.00134	CcSEcCtD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.000218	0.00192	CbGpPWpGaD
Celecoxib—Abdominal pain upper—Doxorubicin—muscle cancer	0.000218	0.00133	CcSEcCtD
Celecoxib—Photosensitivity reaction—Methotrexate—muscle cancer	0.000217	0.00133	CcSEcCtD
Celecoxib—Hypokalaemia—Doxorubicin—muscle cancer	0.000217	0.00133	CcSEcCtD
Celecoxib—Breast disorder—Doxorubicin—muscle cancer	0.000215	0.00132	CcSEcCtD
Celecoxib—Anorexia—Etoposide—muscle cancer	0.000215	0.00132	CcSEcCtD
Celecoxib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000215	0.00131	CcSEcCtD
Celecoxib—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000215	0.00131	CcSEcCtD
Celecoxib—MAPK14—Amyotrophic lateral sclerosis (ALS)—TP53—muscle cancer	0.000214	0.00189	CbGpPWpGaD
Celecoxib—Diarrhoea—Dactinomycin—muscle cancer	0.000214	0.00131	CcSEcCtD
Celecoxib—Pneumonia—Methotrexate—muscle cancer	0.000213	0.00131	CcSEcCtD
Celecoxib—Nasopharyngitis—Doxorubicin—muscle cancer	0.000213	0.00131	CcSEcCtD
Celecoxib—Infestation NOS—Methotrexate—muscle cancer	0.000212	0.0013	CcSEcCtD
Celecoxib—Infestation—Methotrexate—muscle cancer	0.000212	0.0013	CcSEcCtD
Celecoxib—Gastritis—Doxorubicin—muscle cancer	0.000211	0.00129	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.00021	0.00129	CcSEcCtD
Celecoxib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.00021	0.00129	CcSEcCtD
Celecoxib—CA4—Metabolism—FH—muscle cancer	0.00021	0.00185	CbGpPWpGaD
Celecoxib—PDPK1—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.00021	0.00185	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by FGFR in disease—MDM2—muscle cancer	0.00021	0.00185	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 interactions—MDM2—muscle cancer	0.00021	0.00185	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR—MDM2—muscle cancer	0.000208	0.00183	CbGpPWpGaD
Celecoxib—MAPK14—p73 transcription factor network—MDM2—muscle cancer	0.000208	0.00183	CbGpPWpGaD
Celecoxib—Stomatitis—Methotrexate—muscle cancer	0.000207	0.00127	CcSEcCtD
Celecoxib—Conjunctivitis—Methotrexate—muscle cancer	0.000206	0.00126	CcSEcCtD
Celecoxib—Dysphagia—Doxorubicin—muscle cancer	0.000206	0.00126	CcSEcCtD
Celecoxib—PDPK1—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000206	0.00182	CbGpPWpGaD
Celecoxib—Hypersensitivity—Vincristine—muscle cancer	0.000205	0.00126	CcSEcCtD
Celecoxib—PDPK1—Signaling by PDGF—MDM2—muscle cancer	0.000205	0.00181	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—KIDINS220—muscle cancer	0.000205	0.0018	CbGpPWpGaD
Celecoxib—Eosinophilia—Doxorubicin—muscle cancer	0.000204	0.00125	CcSEcCtD
Celecoxib—Paraesthesia—Etoposide—muscle cancer	0.000203	0.00124	CcSEcCtD
Celecoxib—Haematuria—Methotrexate—muscle cancer	0.000202	0.00124	CcSEcCtD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000202	0.00178	CbGpPWpGaD
Celecoxib—Pancreatitis—Doxorubicin—muscle cancer	0.000202	0.00124	CcSEcCtD
Celecoxib—MAPK14—Glucocorticoid receptor regulatory network—MDM2—muscle cancer	0.000202	0.00178	CbGpPWpGaD
Celecoxib—CA2—Metabolism—FH—muscle cancer	0.000202	0.00178	CbGpPWpGaD
Celecoxib—Dyspnoea—Etoposide—muscle cancer	0.000201	0.00123	CcSEcCtD
Celecoxib—Somnolence—Etoposide—muscle cancer	0.000201	0.00123	CcSEcCtD
Celecoxib—Angina pectoris—Doxorubicin—muscle cancer	0.000201	0.00123	CcSEcCtD
Celecoxib—Hepatobiliary disease—Methotrexate—muscle cancer	0.000201	0.00123	CcSEcCtD
Celecoxib—Epistaxis—Methotrexate—muscle cancer	0.0002	0.00123	CcSEcCtD
Celecoxib—ABCC4—Hemostasis—ANGPT2—muscle cancer	0.0002	0.00176	CbGpPWpGaD
Celecoxib—Asthenia—Vincristine—muscle cancer	0.0002	0.00123	CcSEcCtD
Celecoxib—MAPK14—Cellular responses to stress—HMGA1—muscle cancer	0.000199	0.00176	CbGpPWpGaD
Celecoxib—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000199	0.00176	CbGpPWpGaD
Celecoxib—Vomiting—Dactinomycin—muscle cancer	0.000198	0.00122	CcSEcCtD
Celecoxib—Bronchitis—Doxorubicin—muscle cancer	0.000198	0.00121	CcSEcCtD
Celecoxib—Agranulocytosis—Methotrexate—muscle cancer	0.000198	0.00121	CcSEcCtD
Celecoxib—MAPK14—Insulin Signaling—FOXO1—muscle cancer	0.000197	0.00174	CbGpPWpGaD
Celecoxib—Rash—Dactinomycin—muscle cancer	0.000197	0.00121	CcSEcCtD
Celecoxib—Decreased appetite—Etoposide—muscle cancer	0.000196	0.0012	CcSEcCtD
Celecoxib—Pancytopenia—Doxorubicin—muscle cancer	0.000196	0.0012	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Etoposide—muscle cancer	0.000195	0.00119	CcSEcCtD
Celecoxib—MAPK14—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	0.000195	0.00172	CbGpPWpGaD
Celecoxib—Fatigue—Etoposide—muscle cancer	0.000195	0.00119	CcSEcCtD
Celecoxib—PDPK1—B Cell Activation—MDM2—muscle cancer	0.000194	0.00171	CbGpPWpGaD
Celecoxib—Constipation—Etoposide—muscle cancer	0.000193	0.00118	CcSEcCtD
Celecoxib—Dysuria—Doxorubicin—muscle cancer	0.000193	0.00118	CcSEcCtD
Celecoxib—ALB—Platelet degranulation—IGF2—muscle cancer	0.000193	0.0017	CbGpPWpGaD
Celecoxib—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000192	0.00117	CcSEcCtD
Celecoxib—Haemoglobin—Methotrexate—muscle cancer	0.000191	0.00117	CcSEcCtD
Celecoxib—Diarrhoea—Vincristine—muscle cancer	0.000191	0.00117	CcSEcCtD
Celecoxib—Haemorrhage—Methotrexate—muscle cancer	0.00019	0.00117	CcSEcCtD
Celecoxib—Hepatitis—Methotrexate—muscle cancer	0.00019	0.00117	CcSEcCtD
Celecoxib—Pollakiuria—Doxorubicin—muscle cancer	0.00019	0.00117	CcSEcCtD
Celecoxib—PDPK1—Transmission across Chemical Synapses—MDM2—muscle cancer	0.00019	0.00168	CbGpPWpGaD
Celecoxib—Pharyngitis—Methotrexate—muscle cancer	0.000189	0.00116	CcSEcCtD
Celecoxib—ABCC4—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000189	0.00166	CbGpPWpGaD
Celecoxib—Urinary tract disorder—Methotrexate—muscle cancer	0.000188	0.00115	CcSEcCtD
Celecoxib—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000188	0.00115	CcSEcCtD
Celecoxib—Weight increased—Doxorubicin—muscle cancer	0.000188	0.00115	CcSEcCtD
Celecoxib—Urethral disorder—Methotrexate—muscle cancer	0.000187	0.00114	CcSEcCtD
Celecoxib—Feeling abnormal—Etoposide—muscle cancer	0.000186	0.00114	CcSEcCtD
Celecoxib—Hyperglycaemia—Doxorubicin—muscle cancer	0.000186	0.00114	CcSEcCtD
Celecoxib—PDPK1—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000186	0.00164	CbGpPWpGaD
Celecoxib—Nausea—Dactinomycin—muscle cancer	0.000185	0.00114	CcSEcCtD
Celecoxib—Pneumonia—Doxorubicin—muscle cancer	0.000185	0.00113	CcSEcCtD
Celecoxib—Gastrointestinal pain—Etoposide—muscle cancer	0.000185	0.00113	CcSEcCtD
Celecoxib—MAPK14—Oncostatin M Signaling Pathway—VEGFA—muscle cancer	0.000184	0.00163	CbGpPWpGaD
Celecoxib—Dizziness—Vincristine—muscle cancer	0.000184	0.00113	CcSEcCtD
Celecoxib—PDPK1—Innate Immune System—FOXO4—muscle cancer	0.000184	0.00162	CbGpPWpGaD
Celecoxib—Infestation NOS—Doxorubicin—muscle cancer	0.000184	0.00113	CcSEcCtD
Celecoxib—Infestation—Doxorubicin—muscle cancer	0.000184	0.00113	CcSEcCtD
Celecoxib—ALB—Response to elevated platelet cytosolic Ca2+—IGF2—muscle cancer	0.000183	0.00162	CbGpPWpGaD
Celecoxib—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000182	0.00112	CcSEcCtD
Celecoxib—PDPK1—Signaling by NGF—KIT—muscle cancer	0.000181	0.0016	CbGpPWpGaD
Celecoxib—Erythema multiforme—Methotrexate—muscle cancer	0.00018	0.0011	CcSEcCtD
Celecoxib—Neuropathy peripheral—Doxorubicin—muscle cancer	0.00018	0.0011	CcSEcCtD
Celecoxib—Urticaria—Etoposide—muscle cancer	0.000179	0.0011	CcSEcCtD
Celecoxib—Jaundice—Doxorubicin—muscle cancer	0.000179	0.0011	CcSEcCtD
Celecoxib—Stomatitis—Doxorubicin—muscle cancer	0.000179	0.0011	CcSEcCtD
Celecoxib—Abdominal pain—Etoposide—muscle cancer	0.000179	0.00109	CcSEcCtD
Celecoxib—Body temperature increased—Etoposide—muscle cancer	0.000179	0.00109	CcSEcCtD
Celecoxib—Conjunctivitis—Doxorubicin—muscle cancer	0.000179	0.00109	CcSEcCtD
Celecoxib—Urinary tract infection—Doxorubicin—muscle cancer	0.000179	0.00109	CcSEcCtD
Celecoxib—ABCC4—Platelet degranulation—VEGFA—muscle cancer	0.000178	0.00157	CbGpPWpGaD
Celecoxib—Eye disorder—Methotrexate—muscle cancer	0.000178	0.00109	CcSEcCtD
Celecoxib—MAPK14—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—muscle cancer	0.000178	0.00157	CbGpPWpGaD
Celecoxib—Tinnitus—Methotrexate—muscle cancer	0.000178	0.00109	CcSEcCtD
Celecoxib—Vomiting—Vincristine—muscle cancer	0.000177	0.00109	CcSEcCtD
Celecoxib—Cardiac disorder—Methotrexate—muscle cancer	0.000177	0.00108	CcSEcCtD
Celecoxib—CA14—Metabolism—MED12—muscle cancer	0.000177	0.00156	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—FOXO4—muscle cancer	0.000177	0.00156	CbGpPWpGaD
Celecoxib—Rash—Vincristine—muscle cancer	0.000176	0.00108	CcSEcCtD
Celecoxib—Dermatitis—Vincristine—muscle cancer	0.000176	0.00108	CcSEcCtD
Celecoxib—MAPK14—Hemostasis—ANGPT2—muscle cancer	0.000175	0.00154	CbGpPWpGaD
Celecoxib—Haematuria—Doxorubicin—muscle cancer	0.000175	0.00107	CcSEcCtD
Celecoxib—Headache—Vincristine—muscle cancer	0.000175	0.00107	CcSEcCtD
Celecoxib—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000174	0.00106	CcSEcCtD
Celecoxib—Epistaxis—Doxorubicin—muscle cancer	0.000173	0.00106	CcSEcCtD
Celecoxib—Angiopathy—Methotrexate—muscle cancer	0.000173	0.00106	CcSEcCtD
Celecoxib—Sinusitis—Doxorubicin—muscle cancer	0.000172	0.00106	CcSEcCtD
Celecoxib—CA5A—Metabolism—MED12—muscle cancer	0.000172	0.00152	CbGpPWpGaD
Celecoxib—CA6—Metabolism—MED12—muscle cancer	0.000172	0.00152	CbGpPWpGaD
Celecoxib—Immune system disorder—Methotrexate—muscle cancer	0.000172	0.00105	CcSEcCtD
Celecoxib—Mediastinal disorder—Methotrexate—muscle cancer	0.000172	0.00105	CcSEcCtD
Celecoxib—Agranulocytosis—Doxorubicin—muscle cancer	0.000171	0.00105	CcSEcCtD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	0.000171	0.0015	CbGpPWpGaD
Celecoxib—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	0.00017	0.0015	CbGpPWpGaD
Celecoxib—CA9—Metabolism—FH—muscle cancer	0.00017	0.0015	CbGpPWpGaD
Celecoxib—Alopecia—Methotrexate—muscle cancer	0.000168	0.00103	CcSEcCtD
Celecoxib—MAPK14—Signaling by NGF—FOXO4—muscle cancer	0.000168	0.00148	CbGpPWpGaD
Celecoxib—Mental disorder—Methotrexate—muscle cancer	0.000167	0.00102	CcSEcCtD
Celecoxib—Hypersensitivity—Etoposide—muscle cancer	0.000166	0.00102	CcSEcCtD
Celecoxib—Haemoglobin—Doxorubicin—muscle cancer	0.000166	0.00102	CcSEcCtD
Celecoxib—Nausea—Vincristine—muscle cancer	0.000166	0.00101	CcSEcCtD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—MDM2—muscle cancer	0.000166	0.00146	CbGpPWpGaD
Celecoxib—Rhinitis—Doxorubicin—muscle cancer	0.000165	0.00101	CcSEcCtD
Celecoxib—MAPK14—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000165	0.00146	CbGpPWpGaD
Celecoxib—Hepatitis—Doxorubicin—muscle cancer	0.000165	0.00101	CcSEcCtD
Celecoxib—Haemorrhage—Doxorubicin—muscle cancer	0.000165	0.00101	CcSEcCtD
Celecoxib—Hypoaesthesia—Doxorubicin—muscle cancer	0.000164	0.001	CcSEcCtD
Celecoxib—PDPK1—Hemostasis—IGF2—muscle cancer	0.000164	0.00145	CbGpPWpGaD
Celecoxib—Pharyngitis—Doxorubicin—muscle cancer	0.000164	0.001	CcSEcCtD
Celecoxib—Urinary tract disorder—Doxorubicin—muscle cancer	0.000163	0.000997	CcSEcCtD
Celecoxib—Oedema peripheral—Doxorubicin—muscle cancer	0.000162	0.000995	CcSEcCtD
Celecoxib—Dysgeusia—Methotrexate—muscle cancer	0.000162	0.000994	CcSEcCtD
Celecoxib—Asthenia—Etoposide—muscle cancer	0.000162	0.000993	CcSEcCtD
Celecoxib—Connective tissue disorder—Doxorubicin—muscle cancer	0.000162	0.000992	CcSEcCtD
Celecoxib—Urethral disorder—Doxorubicin—muscle cancer	0.000162	0.00099	CcSEcCtD
Celecoxib—CA14—Metabolism—ENO2—muscle cancer	0.000161	0.00142	CbGpPWpGaD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.000161	0.00142	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—MED12—muscle cancer	0.000161	0.00142	CbGpPWpGaD
Celecoxib—PTGS2—C-MYB transcription factor network—KIT—muscle cancer	0.000161	0.00142	CbGpPWpGaD
Celecoxib—Back pain—Methotrexate—muscle cancer	0.00016	0.000982	CcSEcCtD
Celecoxib—Pruritus—Etoposide—muscle cancer	0.00016	0.000979	CcSEcCtD
Celecoxib—MAPK14—Developmental Biology—MYOD1—muscle cancer	0.000159	0.0014	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CD34—muscle cancer	0.000158	0.00139	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—ENO2—muscle cancer	0.000157	0.00138	CbGpPWpGaD
Celecoxib—CA6—Metabolism—ENO2—muscle cancer	0.000157	0.00138	CbGpPWpGaD
Celecoxib—Vision blurred—Methotrexate—muscle cancer	0.000156	0.000957	CcSEcCtD
Celecoxib—Erythema multiforme—Doxorubicin—muscle cancer	0.000156	0.000955	CcSEcCtD
Celecoxib—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.000155	0.00137	CbGpPWpGaD
Celecoxib—Diarrhoea—Etoposide—muscle cancer	0.000155	0.000947	CcSEcCtD
Celecoxib—MAPK14—Oxidative Stress Induced Senescence—CDKN2A—muscle cancer	0.000154	0.00136	CbGpPWpGaD
Celecoxib—Eye disorder—Doxorubicin—muscle cancer	0.000154	0.000944	CcSEcCtD
Celecoxib—Tinnitus—Doxorubicin—muscle cancer	0.000154	0.000942	CcSEcCtD
Celecoxib—Anaemia—Methotrexate—muscle cancer	0.000153	0.000938	CcSEcCtD
Celecoxib—Cardiac disorder—Doxorubicin—muscle cancer	0.000153	0.000937	CcSEcCtD
Celecoxib—Flushing—Doxorubicin—muscle cancer	0.000153	0.000937	CcSEcCtD
Celecoxib—MAPK14—p53 pathway—TP53—muscle cancer	0.000151	0.00133	CbGpPWpGaD
Celecoxib—PDPK1—Focal Adhesion—VEGFA—muscle cancer	0.000151	0.00133	CbGpPWpGaD
Celecoxib—MAPK14—Oxidative Stress Induced Senescence—MDM2—muscle cancer	0.00015	0.00132	CbGpPWpGaD
Celecoxib—Angiopathy—Doxorubicin—muscle cancer	0.00015	0.000916	CcSEcCtD
Celecoxib—Dizziness—Etoposide—muscle cancer	0.000149	0.000915	CcSEcCtD
Celecoxib—Immune system disorder—Doxorubicin—muscle cancer	0.000149	0.000912	CcSEcCtD
Celecoxib—Vertigo—Methotrexate—muscle cancer	0.000149	0.000912	CcSEcCtD
Celecoxib—CA12—Metabolism—MED12—muscle cancer	0.000149	0.00131	CbGpPWpGaD
Celecoxib—Mediastinal disorder—Doxorubicin—muscle cancer	0.000149	0.00091	CcSEcCtD
Celecoxib—Leukopenia—Methotrexate—muscle cancer	0.000148	0.000909	CcSEcCtD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000148	0.0013	CbGpPWpGaD
Celecoxib—Arrhythmia—Doxorubicin—muscle cancer	0.000147	0.000902	CcSEcCtD
Celecoxib—CA5B—Metabolism—ENO2—muscle cancer	0.000147	0.00129	CbGpPWpGaD
Celecoxib—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	0.000146	0.00129	CbGpPWpGaD
Celecoxib—PDPK1—Neuronal System—MDM2—muscle cancer	0.000146	0.00129	CbGpPWpGaD
Celecoxib—Alopecia—Doxorubicin—muscle cancer	0.000146	0.000892	CcSEcCtD
Celecoxib—MAPK14—Developmental Biology—MED12—muscle cancer	0.000146	0.00128	CbGpPWpGaD
Celecoxib—Cough—Methotrexate—muscle cancer	0.000145	0.000886	CcSEcCtD
Celecoxib—Mental disorder—Doxorubicin—muscle cancer	0.000145	0.000885	CcSEcCtD
Celecoxib—Vomiting—Etoposide—muscle cancer	0.000144	0.00088	CcSEcCtD
Celecoxib—PDPK1—Signaling by NGF—MDM2—muscle cancer	0.000143	0.00126	CbGpPWpGaD
Celecoxib—Rash—Etoposide—muscle cancer	0.000142	0.000872	CcSEcCtD
Celecoxib—Dermatitis—Etoposide—muscle cancer	0.000142	0.000871	CcSEcCtD
Celecoxib—Headache—Etoposide—muscle cancer	0.000142	0.000867	CcSEcCtD
Celecoxib—Flatulence—Doxorubicin—muscle cancer	0.000141	0.000866	CcSEcCtD
Celecoxib—Myalgia—Methotrexate—muscle cancer	0.000141	0.000864	CcSEcCtD
Celecoxib—Arthralgia—Methotrexate—muscle cancer	0.000141	0.000864	CcSEcCtD
Celecoxib—Chest pain—Methotrexate—muscle cancer	0.000141	0.000864	CcSEcCtD
Celecoxib—Tension—Doxorubicin—muscle cancer	0.000141	0.000863	CcSEcCtD
Celecoxib—Dysgeusia—Doxorubicin—muscle cancer	0.000141	0.000861	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00014	0.000858	CcSEcCtD
Celecoxib—Nervousness—Doxorubicin—muscle cancer	0.000139	0.000854	CcSEcCtD
Celecoxib—MAPK14—Oncostatin M Signaling Pathway—TP53—muscle cancer	0.000139	0.00123	CbGpPWpGaD
Celecoxib—Back pain—Doxorubicin—muscle cancer	0.000139	0.00085	CcSEcCtD
Celecoxib—Muscle spasms—Doxorubicin—muscle cancer	0.000138	0.000845	CcSEcCtD
Celecoxib—Confusional state—Methotrexate—muscle cancer	0.000136	0.000836	CcSEcCtD
Celecoxib—PDPK1—Signaling by GPCR—PTCH1—muscle cancer	0.000136	0.0012	CbGpPWpGaD
Celecoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—TP53—muscle cancer	0.000136	0.0012	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—FOXO1—muscle cancer	0.000136	0.0012	CbGpPWpGaD
Celecoxib—CA12—Metabolism—ENO2—muscle cancer	0.000136	0.0012	CbGpPWpGaD
Celecoxib—Anaphylactic shock—Methotrexate—muscle cancer	0.000135	0.000829	CcSEcCtD
Celecoxib—Vision blurred—Doxorubicin—muscle cancer	0.000135	0.000829	CcSEcCtD
Celecoxib—CA9—Cellular responses to stress—CDKN2A—muscle cancer	0.000135	0.00119	CbGpPWpGaD
Celecoxib—Infection—Methotrexate—muscle cancer	0.000134	0.000823	CcSEcCtD
Celecoxib—Nausea—Etoposide—muscle cancer	0.000134	0.000822	CcSEcCtD
Celecoxib—PDPK1—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	0.000133	0.00118	CbGpPWpGaD
Celecoxib—Nervous system disorder—Methotrexate—muscle cancer	0.000133	0.000813	CcSEcCtD
Celecoxib—Anaemia—Doxorubicin—muscle cancer	0.000133	0.000813	CcSEcCtD
Celecoxib—Thrombocytopenia—Methotrexate—muscle cancer	0.000133	0.000811	CcSEcCtD
Celecoxib—Skin disorder—Methotrexate—muscle cancer	0.000131	0.000805	CcSEcCtD
Celecoxib—CA9—Cellular responses to stress—MDM2—muscle cancer	0.000131	0.00116	CbGpPWpGaD
Celecoxib—Hyperhidrosis—Methotrexate—muscle cancer	0.000131	0.000801	CcSEcCtD
Celecoxib—PDPK1—Adaptive Immune System—FOXO1—muscle cancer	0.00013	0.00115	CbGpPWpGaD
Celecoxib—PTGS2—C-MYB transcription factor network—CDKN2A—muscle cancer	0.00013	0.00115	CbGpPWpGaD
Celecoxib—Vertigo—Doxorubicin—muscle cancer	0.000129	0.00079	CcSEcCtD
Celecoxib—Anorexia—Methotrexate—muscle cancer	0.000129	0.00079	CcSEcCtD
Celecoxib—Syncope—Doxorubicin—muscle cancer	0.000129	0.000788	CcSEcCtD
Celecoxib—Leukopenia—Doxorubicin—muscle cancer	0.000129	0.000787	CcSEcCtD
Celecoxib—Palpitations—Doxorubicin—muscle cancer	0.000127	0.000777	CcSEcCtD
Celecoxib—PDPK1—GPCR downstream signaling—CNR1—muscle cancer	0.000127	0.00112	CbGpPWpGaD
Celecoxib—Loss of consciousness—Doxorubicin—muscle cancer	0.000126	0.000773	CcSEcCtD
Celecoxib—Cough—Doxorubicin—muscle cancer	0.000125	0.000767	CcSEcCtD
Celecoxib—Hypertension—Doxorubicin—muscle cancer	0.000124	0.000759	CcSEcCtD
Celecoxib—MAPK14—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	0.000124	0.00109	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—FOXO1—muscle cancer	0.000124	0.00109	CbGpPWpGaD
Celecoxib—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000123	0.000755	CcSEcCtD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000123	0.00108	CbGpPWpGaD
Celecoxib—Insomnia—Methotrexate—muscle cancer	0.000122	0.000749	CcSEcCtD
Celecoxib—Arthralgia—Doxorubicin—muscle cancer	0.000122	0.000748	CcSEcCtD
Celecoxib—Chest pain—Doxorubicin—muscle cancer	0.000122	0.000748	CcSEcCtD
Celecoxib—Myalgia—Doxorubicin—muscle cancer	0.000122	0.000748	CcSEcCtD
Celecoxib—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000122	0.00108	CbGpPWpGaD
Celecoxib—Anxiety—Doxorubicin—muscle cancer	0.000122	0.000746	CcSEcCtD
Celecoxib—Paraesthesia—Methotrexate—muscle cancer	0.000122	0.000744	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000121	0.000743	CcSEcCtD
Celecoxib—PDPK1—Disease—ENO2—muscle cancer	0.000121	0.00107	CbGpPWpGaD
Celecoxib—Dyspnoea—Methotrexate—muscle cancer	0.000121	0.000739	CcSEcCtD
Celecoxib—Somnolence—Methotrexate—muscle cancer	0.00012	0.000737	CcSEcCtD
Celecoxib—Dry mouth—Doxorubicin—muscle cancer	0.00012	0.000732	CcSEcCtD
Celecoxib—Dyspepsia—Methotrexate—muscle cancer	0.000119	0.000729	CcSEcCtD
Celecoxib—CA4—Metabolism—MED12—muscle cancer	0.000119	0.00105	CbGpPWpGaD
Celecoxib—Confusional state—Doxorubicin—muscle cancer	0.000118	0.000723	CcSEcCtD
Celecoxib—Decreased appetite—Methotrexate—muscle cancer	0.000118	0.00072	CcSEcCtD
Celecoxib—Oedema—Doxorubicin—muscle cancer	0.000117	0.000718	CcSEcCtD
Celecoxib—Anaphylactic shock—Doxorubicin—muscle cancer	0.000117	0.000718	CcSEcCtD
Celecoxib—MAPK14—Signaling by VEGF—VEGFA—muscle cancer	0.000117	0.00103	CbGpPWpGaD
Celecoxib—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000117	0.000715	CcSEcCtD
Celecoxib—Fatigue—Methotrexate—muscle cancer	0.000117	0.000714	CcSEcCtD
Celecoxib—Infection—Doxorubicin—muscle cancer	0.000116	0.000713	CcSEcCtD
Celecoxib—MAPK14—Glucocorticoid receptor regulatory network—TP53—muscle cancer	0.000116	0.00102	CbGpPWpGaD
Celecoxib—Shock—Doxorubicin—muscle cancer	0.000115	0.000706	CcSEcCtD
Celecoxib—PDPK1—Signaling by GPCR—CNR1—muscle cancer	0.000115	0.00101	CbGpPWpGaD
Celecoxib—Nervous system disorder—Doxorubicin—muscle cancer	0.000115	0.000704	CcSEcCtD
Celecoxib—Thrombocytopenia—Doxorubicin—muscle cancer	0.000115	0.000703	CcSEcCtD
Celecoxib—Tachycardia—Doxorubicin—muscle cancer	0.000114	0.0007	CcSEcCtD
Celecoxib—CA2—Metabolism—MED12—muscle cancer	0.000114	0.001	CbGpPWpGaD
Celecoxib—Skin disorder—Doxorubicin—muscle cancer	0.000114	0.000697	CcSEcCtD
Celecoxib—Hyperhidrosis—Doxorubicin—muscle cancer	0.000113	0.000694	CcSEcCtD
Celecoxib—Anorexia—Doxorubicin—muscle cancer	0.000112	0.000684	CcSEcCtD
Celecoxib—Feeling abnormal—Methotrexate—muscle cancer	0.000112	0.000683	CcSEcCtD
Celecoxib—Gastrointestinal pain—Methotrexate—muscle cancer	0.000111	0.000678	CcSEcCtD
Celecoxib—PDPK1—Disease—HMGA1—muscle cancer	0.00011	0.000972	CbGpPWpGaD
Celecoxib—CA4—Metabolism—ENO2—muscle cancer	0.000108	0.000955	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—CDKN2A—muscle cancer	0.000108	0.000952	CbGpPWpGaD
Celecoxib—Urticaria—Methotrexate—muscle cancer	0.000108	0.000658	CcSEcCtD
Celecoxib—PDPK1—Immune System—FOXO4—muscle cancer	0.000107	0.000944	CbGpPWpGaD
Celecoxib—Abdominal pain—Methotrexate—muscle cancer	0.000107	0.000655	CcSEcCtD
Celecoxib—Body temperature increased—Methotrexate—muscle cancer	0.000107	0.000655	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000107	0.000654	CcSEcCtD
Celecoxib—MAPK14—Signaling Pathways—KIDINS220—muscle cancer	0.000106	0.000937	CbGpPWpGaD
Celecoxib—Insomnia—Doxorubicin—muscle cancer	0.000106	0.000649	CcSEcCtD
Celecoxib—Paraesthesia—Doxorubicin—muscle cancer	0.000105	0.000644	CcSEcCtD
Celecoxib—MAPK14—Cellular Senescence—MDM2—muscle cancer	0.000105	0.000924	CbGpPWpGaD
Celecoxib—Dyspnoea—Doxorubicin—muscle cancer	0.000104	0.00064	CcSEcCtD
Celecoxib—Somnolence—Doxorubicin—muscle cancer	0.000104	0.000638	CcSEcCtD
Celecoxib—CA2—Metabolism—ENO2—muscle cancer	0.000104	0.000915	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—KIT—muscle cancer	0.000103	0.000912	CbGpPWpGaD
Celecoxib—Dyspepsia—Doxorubicin—muscle cancer	0.000103	0.000632	CcSEcCtD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000103	0.000904	CbGpPWpGaD
Celecoxib—Decreased appetite—Doxorubicin—muscle cancer	0.000102	0.000624	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000101	0.000619	CcSEcCtD
Celecoxib—Fatigue—Doxorubicin—muscle cancer	0.000101	0.000619	CcSEcCtD
Celecoxib—Constipation—Doxorubicin—muscle cancer	0.0001	0.000614	CcSEcCtD
Celecoxib—Hypersensitivity—Methotrexate—muscle cancer	9.97e-05	0.000611	CcSEcCtD
Celecoxib—CA9—Cellular responses to stress—VEGFA—muscle cancer	9.96e-05	0.000879	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—KIT—muscle cancer	9.94e-05	0.000876	CbGpPWpGaD
Celecoxib—PDPK1—Disease—FOXO4—muscle cancer	9.89e-05	0.000872	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	9.89e-05	0.000872	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—IGF2—muscle cancer	9.73e-05	0.000858	CbGpPWpGaD
Celecoxib—Asthenia—Methotrexate—muscle cancer	9.71e-05	0.000595	CcSEcCtD
Celecoxib—Feeling abnormal—Doxorubicin—muscle cancer	9.66e-05	0.000591	CcSEcCtD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	9.66e-05	0.000851	CbGpPWpGaD
Celecoxib—CA9—Metabolism—MED12—muscle cancer	9.6e-05	0.000846	CbGpPWpGaD
Celecoxib—Gastrointestinal pain—Doxorubicin—muscle cancer	9.58e-05	0.000587	CcSEcCtD
Celecoxib—Pruritus—Methotrexate—muscle cancer	9.57e-05	0.000586	CcSEcCtD
Celecoxib—MAPK14—Innate Immune System—FOXO4—muscle cancer	9.56e-05	0.000843	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—PTGS2—muscle cancer	9.5e-05	0.000838	CbGpPWpGaD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—TP53—muscle cancer	9.5e-05	0.000837	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—KIT—muscle cancer	9.43e-05	0.000831	CbGpPWpGaD
Celecoxib—Urticaria—Doxorubicin—muscle cancer	9.31e-05	0.00057	CcSEcCtD
Celecoxib—Abdominal pain—Doxorubicin—muscle cancer	9.26e-05	0.000567	CcSEcCtD
Celecoxib—Body temperature increased—Doxorubicin—muscle cancer	9.26e-05	0.000567	CcSEcCtD
Celecoxib—Diarrhoea—Methotrexate—muscle cancer	9.26e-05	0.000567	CcSEcCtD
Celecoxib—ALB—Hemostasis—ANGPT2—muscle cancer	9.06e-05	0.000798	CbGpPWpGaD
Celecoxib—Dizziness—Methotrexate—muscle cancer	8.95e-05	0.000548	CcSEcCtD
Celecoxib—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	8.94e-05	0.000788	CbGpPWpGaD
Celecoxib—CA9—Metabolism—ENO2—muscle cancer	8.75e-05	0.000772	CbGpPWpGaD
Celecoxib—Hypersensitivity—Doxorubicin—muscle cancer	8.63e-05	0.000529	CcSEcCtD
Celecoxib—Vomiting—Methotrexate—muscle cancer	8.6e-05	0.000527	CcSEcCtD
Celecoxib—MAPK14—Oxidative Stress Induced Senescence—TP53—muscle cancer	8.59e-05	0.000758	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—IGF2—muscle cancer	8.54e-05	0.000753	CbGpPWpGaD
Celecoxib—Rash—Methotrexate—muscle cancer	8.53e-05	0.000522	CcSEcCtD
Celecoxib—Dermatitis—Methotrexate—muscle cancer	8.53e-05	0.000522	CcSEcCtD
Celecoxib—MAPK14—Hemostasis—IGF2—muscle cancer	8.52e-05	0.000751	CbGpPWpGaD
Celecoxib—Headache—Methotrexate—muscle cancer	8.48e-05	0.000519	CcSEcCtD
Celecoxib—Asthenia—Doxorubicin—muscle cancer	8.41e-05	0.000515	CcSEcCtD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	8.31e-05	0.000732	CbGpPWpGaD
Celecoxib—Pruritus—Doxorubicin—muscle cancer	8.29e-05	0.000508	CcSEcCtD
Celecoxib—MAPK14—Immune System—CD34—muscle cancer	8.19e-05	0.000722	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—CDKN2A—muscle cancer	8.16e-05	0.00072	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—MDM2—muscle cancer	8.15e-05	0.000719	CbGpPWpGaD
Celecoxib—ALB—Platelet degranulation—VEGFA—muscle cancer	8.08e-05	0.000712	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PTCH1—muscle cancer	8.05e-05	0.00071	CbGpPWpGaD
Celecoxib—Nausea—Methotrexate—muscle cancer	8.04e-05	0.000492	CcSEcCtD
Celecoxib—Diarrhoea—Doxorubicin—muscle cancer	8.02e-05	0.000491	CcSEcCtD
Celecoxib—MAPK14—Developmental Biology—FOXO1—muscle cancer	7.99e-05	0.000705	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—MDM2—muscle cancer	7.92e-05	0.000698	CbGpPWpGaD
Celecoxib—ABCC4—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	7.92e-05	0.000698	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—FOXO1—muscle cancer	7.91e-05	0.000697	CbGpPWpGaD
Celecoxib—MAPK14—TGF-beta Signaling Pathway—TP53—muscle cancer	7.91e-05	0.000697	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—MDM2—muscle cancer	7.83e-05	0.00069	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	7.79e-05	0.000687	CbGpPWpGaD
Celecoxib—Dizziness—Doxorubicin—muscle cancer	7.75e-05	0.000474	CcSEcCtD
Celecoxib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	7.69e-05	0.000678	CbGpPWpGaD
Celecoxib—CA9—Cellular responses to stress—TP53—muscle cancer	7.53e-05	0.000664	CbGpPWpGaD
Celecoxib—Vomiting—Doxorubicin—muscle cancer	7.45e-05	0.000456	CcSEcCtD
Celecoxib—MAPK14—Gene Expression—MED12—muscle cancer	7.45e-05	0.000657	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—MDM2—muscle cancer	7.43e-05	0.000655	CbGpPWpGaD
Celecoxib—Rash—Doxorubicin—muscle cancer	7.39e-05	0.000452	CcSEcCtD
Celecoxib—Dermatitis—Doxorubicin—muscle cancer	7.38e-05	0.000452	CcSEcCtD
Celecoxib—Headache—Doxorubicin—muscle cancer	7.34e-05	0.00045	CcSEcCtD
Celecoxib—PDPK1—Disease—FOXO1—muscle cancer	7.3e-05	0.000644	CbGpPWpGaD
Celecoxib—ALB—Folate Metabolism—TP53—muscle cancer	7.12e-05	0.000628	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—FOXO1—muscle cancer	7.06e-05	0.000622	CbGpPWpGaD
Celecoxib—Nausea—Doxorubicin—muscle cancer	6.96e-05	0.000426	CcSEcCtD
Celecoxib—MAPK14—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	6.93e-05	0.000611	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—FOXO4—muscle cancer	6.93e-05	0.000611	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—VEGFA—muscle cancer	6.88e-05	0.000606	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CNR1—muscle cancer	6.8e-05	0.000599	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—MED12—muscle cancer	6.72e-05	0.000593	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	6.55e-05	0.000578	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—FH—muscle cancer	6.55e-05	0.000577	CbGpPWpGaD
Celecoxib—MAPK14—MAPK Signaling Pathway—TP53—muscle cancer	6.52e-05	0.000575	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—KIT—muscle cancer	6.03e-05	0.000531	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—VEGFA—muscle cancer	6.01e-05	0.00053	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—TP53—muscle cancer	6.01e-05	0.00053	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	5.89e-05	0.000519	CbGpPWpGaD
Celecoxib—CA14—Metabolism—PTGS2—muscle cancer	5.61e-05	0.000495	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—FOXO4—muscle cancer	5.57e-05	0.000491	CbGpPWpGaD
Celecoxib—PDPK1—Disease—KIT—muscle cancer	5.57e-05	0.000491	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IGF2—muscle cancer	5.56e-05	0.00049	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—TP53—muscle cancer	5.53e-05	0.000487	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	5.5e-05	0.000485	CbGpPWpGaD
Celecoxib—CA6—Metabolism—PTGS2—muscle cancer	5.47e-05	0.000482	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—PTGS2—muscle cancer	5.47e-05	0.000482	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—KIT—muscle cancer	5.38e-05	0.000474	CbGpPWpGaD
Celecoxib—ALB—Metabolism—FH—muscle cancer	5.3e-05	0.000467	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—TP53—muscle cancer	5.19e-05	0.000458	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—FOXO1—muscle cancer	5.11e-05	0.000451	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—PTGS2—muscle cancer	5.11e-05	0.00045	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	4.98e-05	0.000439	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—MDM2—muscle cancer	4.75e-05	0.000419	CbGpPWpGaD
Celecoxib—CA12—Metabolism—PTGS2—muscle cancer	4.73e-05	0.000417	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—TP53—muscle cancer	4.54e-05	0.000401	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—IGF2—muscle cancer	4.4e-05	0.000388	CbGpPWpGaD
Celecoxib—PDPK1—Disease—MDM2—muscle cancer	4.38e-05	0.000386	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—FH—muscle cancer	4.37e-05	0.000386	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—FH—muscle cancer	4.34e-05	0.000382	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—MDM2—muscle cancer	4.24e-05	0.000373	CbGpPWpGaD
Celecoxib—PDPK1—Disease—PTGS2—muscle cancer	4.23e-05	0.000373	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTCH1—muscle cancer	4.19e-05	0.000369	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—FOXO1—muscle cancer	4.11e-05	0.000362	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—VEGFA—muscle cancer	4.08e-05	0.00036	CbGpPWpGaD
Celecoxib—PTGS2—Disease—ENO2—muscle cancer	4.03e-05	0.000355	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—KIT—muscle cancer	3.9e-05	0.000344	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PTGS2—muscle cancer	3.77e-05	0.000333	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.76e-05	0.000331	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—MED12—muscle cancer	3.7e-05	0.000326	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HMGA1—muscle cancer	3.66e-05	0.000323	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—VEGFA—muscle cancer	3.64e-05	0.000321	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PTGS2—muscle cancer	3.62e-05	0.000319	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FOXO4—muscle cancer	3.6e-05	0.000317	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	3.58e-05	0.000316	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—VEGFA—muscle cancer	3.57e-05	0.000315	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CNR1—muscle cancer	3.53e-05	0.000311	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ENO2—muscle cancer	3.37e-05	0.000297	CbGpPWpGaD
Celecoxib—PTGS2—Disease—FOXO4—muscle cancer	3.28e-05	0.000289	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—KIT—muscle cancer	3.13e-05	0.000276	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—TP53—muscle cancer	3.08e-05	0.000272	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MDM2—muscle cancer	3.07e-05	0.000271	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PTGS2—muscle cancer	3.05e-05	0.000269	CbGpPWpGaD
Celecoxib—ALB—Metabolism—MED12—muscle cancer	2.99e-05	0.000264	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IGF2—muscle cancer	2.89e-05	0.000255	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—FH—muscle cancer	2.86e-05	0.000252	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ENO2—muscle cancer	2.73e-05	0.000241	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—TP53—muscle cancer	2.7e-05	0.000238	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FOXO1—muscle cancer	2.66e-05	0.000234	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—MED12—muscle cancer	2.47e-05	0.000218	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—MDM2—muscle cancer	2.47e-05	0.000218	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—MED12—muscle cancer	2.45e-05	0.000216	CbGpPWpGaD
Celecoxib—PTGS2—Disease—FOXO1—muscle cancer	2.42e-05	0.000214	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—VEGFA—muscle cancer	2.33e-05	0.000205	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ENO2—muscle cancer	2.25e-05	0.000199	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ENO2—muscle cancer	2.23e-05	0.000197	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.13e-05	0.000188	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KIT—muscle cancer	2.03e-05	0.000179	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KIT—muscle cancer	1.85e-05	0.000163	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—VEGFA—muscle cancer	1.85e-05	0.000163	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TP53—muscle cancer	1.76e-05	0.000155	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.75e-05	0.000154	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—MED12—muscle cancer	1.62e-05	0.000142	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MDM2—muscle cancer	1.6e-05	0.000141	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ENO2—muscle cancer	1.47e-05	0.00013	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MDM2—muscle cancer	1.46e-05	0.000128	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TP53—muscle cancer	1.4e-05	0.000123	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—VEGFA—muscle cancer	1.21e-05	0.000107	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTGS2—muscle cancer	9.5e-06	8.38e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TP53—muscle cancer	9.15e-06	8.07e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTGS2—muscle cancer	7.85e-06	6.92e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTGS2—muscle cancer	7.78e-06	6.86e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTGS2—muscle cancer	5.13e-06	4.52e-05	CbGpPWpGaD
